Nektar Therapeutics vs Ocular Therapeutix
Nektar Therapeutics reported revenue of $55 million in fiscal 2025, about the same as Ocular Therapeutix's $52 million in fiscal 2025. Nektar Therapeutics' revenue fell 43.9% in its latest year, and Ocular Therapeutix's fell 18.5%. Nektar Therapeutics had an operating margin of -253.7%, against -519.8% at Ocular Therapeutix. Free cash flow was −$209 million at Nektar Therapeutics and −$217 million at Ocular Therapeutix.
Side by side
| Nektar Therapeutics | Ocular Therapeutix | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $55M | $52M |
| Revenue growth | −43.9% | −18.5% |
| Revenue growth a year, last 5 years | −18.4% | 24.5% |
| Gross margin | 100.0% | 87.3% |
| Operating margin | −253.7% | −519.8% |
| Net margin | −297.1% | −511.9% |
| Free cash flow | −$209M | −$217M |
| Free cash flow margin | −377.8% | −417.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.1% | 18.3% |
| Last close | $37.27 | $6.21 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.4 million | bought $461,354, sold $2.8 million |
| Piotroski F-score | 2 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Nektar TherapeuticsOcular Therapeutix
Operating margin
Percent of revenue
Nektar TherapeuticsOcular Therapeutix
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nektar TherapeuticsOcular Therapeutix
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nektar Therapeutics and Ocular Therapeutix pages.